Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 Sativex for spasticity due to multiple sclerosis
2006-005910-11Phase 3Completed
- Sponsor
- GW Pharmaceuticals
- Start
- Jul 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of cannabidiol in multiple sclerosis (MS) (3 arms), sponsored by GW Pharmaceuticals. Started Jul 2007; status: completed.
02
Drugs
cannabidiol
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on 2006-005910-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-005910-11.